|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Bronchial Allergen Challenge Study to Assess the Safety, Tolerability, and Efficacy of Inhaled AIR645 in Subjects With Mild Allergic Asthma
To assess the efficacy of inhaled AIR645 in the suppression of the Asthmatic Responses in subjects with mild asthma inhaling an allergen.
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma
This is a phase one study to evaluate the safety, tolerability, and bioavailability of nebulized AIR645.
100 项与 Altair Therapeutics, Inc. 相关的临床结果
0 项与 Altair Therapeutics, Inc. 相关的专利(医药)
100 项与 Altair Therapeutics, Inc. 相关的药物交易
100 项与 Altair Therapeutics, Inc. 相关的转化医学